

ABPI Disclosure Database Methodological Note 2016

Introduction

STD Pharmaceutical Products Ltd is a small family run business formed in 1967 and based in Hereford. The company manufactures Fibrovein, a detergent based sclerosant, which is licensed for the treatment of varicose veins. The company also manufactures and/or procures products to support the use of the Fibrovein in sclerotherapy.

Fibrovein is currently licensed in 22 countries. The arrangement with each country varies but generally there is a distributor and often a local regulatory agent. In the majority of countries, STD Pharmaceutical Products Ltd has little direct interaction with Healthcare Professionals (HCPs), Healthcare Organisations (HCOs) or other relevant decision makers (ORDMs).

Methodology

The Managing Director and the Financial Controller of STD Pharmaceutical Products Ltd identified all account codes that could possibly include transfers of value to HCPs, HCOs and ORDMs. All transactions relating to these codes were retrieved and screened to identify relevant transfers of value which have been included in the Disclosure Database of Payments.

The value of transfers was in UK Pounds Sterling. The transfer of values on the template in all instances is the gross amount which may or may not have included VAT and the recipients were responsible for any tax liabilities.

Most of the transfers were to UK hospital trusts or clinics. Consent has been sought for disclosures to individual healthcare professionals; where this was not received, or refused, these have been included in the aggregate amounts.

Transfers of value for meals at meetings with healthcare professionals were very few but complied with the guidance of Clause 22.2 of the PMCPA Code of Practice and were not disclosed in the template.